Skip to content

Scholar Rock SRRK Net Investment in Lease

Net Investment in Lease at other companies

Biogen logo
BiogenBIIB
PTC Therapeutics logo
PTC TherapeuticsPTCT
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%
Enterprise value$5.45B+82.6%
P/S170.9×

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's net investment in lease?
Scholar Rock (SRRK) reported net investment in lease of $10.14M in Q1 2026.
How has Scholar Rock's net investment in lease changed year-over-year?
Scholar Rock's net investment in lease decreased by 29.6% year-over-year, from $14.4M to $10.14M.
What is the long-term trend for Scholar Rock's net investment in lease?
Over 5 years (2020 to 2025), Scholar Rock's net investment in lease has grown at a -20.3% compound annual growth rate (CAGR), from $32.26M to $10.38M.